



(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/864 (2006.01)
A61P 3/00 (2006.01) C12N 9/00 (2006.01)
A61P 7/00 (2006.01) A61K 35/76 (2015.01)
C12N 15/86 (2006.01) A61K 38/44 (2006.01)

(21) International Application Number:

PCT/US2024/058985

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/607,089 06 December 2023 (06.12.2023) US

(71) Applicant: OYSTER POINT PHARMA, INC. [US/US];

202 Carnegie Center, Suite 106, Princeton, New Jersey
08540 (US).

(72) Inventors: CARLSON, Eric C.; c/o OYSTER POINT

PHARMA, INC., 202 Carnegie Center, Suite 106, Prince-

ton, New Jersey 08540 (US). CHITTESTER, Dessa; c/o
OYSTER POINT PHARMA, INC., 202 Carnegie Center,
Suite 106, Princeton, New Jersey 08540 (US).

(74) Agent: SCARPATI, Michael et al.; Arent Fox Schiff LLP
(NY), 1717 K Street, NW, Washington, District of Colum-
bia 20006-5344 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: AAV VECTOR ENCODING DIAMINE OXIDASE AND USES THEREOF




FIG. 1A

(57) Abstract: Provided are vectors (e.g., recombinant adeno-associated virus, "rAAV" vectors), methods of treating a condition (e.g., a condition associated with excess histamine or histamine-induced inflammation), pharmaceutical compositions, and other compositions and methods, in which the vector comprises a polynucleotide encoding a diamine oxidase ("DAOI"). Methods of treatment may include administration to the salivary glands (e.g., a parotid gland) of a subject.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))